Literature DB >> 12006216

Changes in mu opioid receptors and rheological properties of erythrocytes among opioid abusers.

Allen R Zeiger1, Ashwin A Patkar, Raina Fitzgerald, Allan Lundy, Samir K Ballas, Stephen P Weinstein.   

Abstract

Opioids, reported originally to bind to specific receptors in the brain, now also appear to bind to receptors on blood cells. The high prevalence of anemia among chronic opioid users leads us to propose that chronic opiate use results in elevated mu opioid receptor levels on human erythrocytes and that these receptor changes may affect erythrocyte membrane properties. Blood samples from 17 opioid-dependent subjects (based on the Diagnostic and Statistical Manual of Mental Disorders, 4th edition or DSM-IV) and 15 drug-free controls were assayed for mu opioid receptors on erythrocytes using a flow cytometry immunoassay. Deformability and the hydration status of erythrocytes were studied by ektacytometry. Data were analyzed by independent t-tests, tests of correlation, chi square and cluster analyses. As expected, the percentage of erythrocytes from opioid-dependent subjects with opioid receptors (opioid receptor levels) was significantly higher (47.4 +/- 38.3%) than controls (22.8 +/- 30.1%) (t = 2.01, df = 30, p < 0.05). Also, the opioid-dependent patients showed a wide variation in the percentage of erythrocytes bearing opioid receptors and data analyses of these patients showed two strongly defined clusters. One subgroup consisted of nine individuals with very high receptor levels (mean = 81.5%) while the other had eight patients with low receptor levels (mean = 9.1%) that were not significantly different than the receptor levels of controls. Ektacytometry of opioid dependent patients with high opioid receptor levels showed changes in rheological parameters of erythrocytes, such as deformability index and cellular hydration. For example, a positive correlation was observed between opioid receptor levels and deformability indices among opioid-dependent patients (r = 0.74, p < 0.005). Our findings indicate that the mu opioid receptor is present on human erythrocytes, although with considerable variation in receptor levels, and that the levels of this receptor are significantly elevated with chronic opioid exposure. Moreover, erythrocytes with high opioid receptor levels from chronic opiate users seem to have high deformability. This study may offer clues to the biological properties of peripheral blood cells that may be mediated by mu opioid receptors and lead to a better understanding of some of the clinical effects of opioid use.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12006216     DOI: 10.1080/135562102200120433

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  5 in total

1.  Preoperative opiate use leads to increased postoperative opiate use and readmissions after anterior cervical discectomy and fusion.

Authors:  Jun Ho Chung; Alex Mierke; Omar Ramos; Whitney Kagabo; Warren Boling; Wayne Cheng; Olumide Danisa
Journal:  J Spine Surg       Date:  2022-06

Review 2.  Morphine for the treatment of pain in sickle cell disease.

Authors:  Mihir Gupta; Lilian Msambichaka; Samir K Ballas; Kalpna Gupta
Journal:  ScientificWorldJournal       Date:  2015-01-12

3.  Evidence on the Heroin-Mediated Impairment of the Oxidative Status of Erythrocytes.

Authors:  Mohammad A Bani-Ahmad; Ayman G Mustafa; Abdelraheem A Bani Ahmad; Islam E Alkhazali; Ahmad A Rahim
Journal:  J Toxicol       Date:  2022-09-28

4.  Macrocytosis among patients with heroin use disorder.

Authors:  Mei-Hing Ng; Vincent Chin-Hung Chen; Hua Ting; Tsang-Yaw Lin; Sheng-Huang Chang; Michael Gossop
Journal:  Neuropsychiatr Dis Treat       Date:  2019-08-12       Impact factor: 2.570

5.  Genome-wide association study of problematic opioid prescription use in 132,113 23andMe research participants of European ancestry.

Authors:  Sandra Sanchez-Roige; Pierre Fontanillas; Mariela V Jennings; Sevim B Bianchi; Yuye Huang; Alexander S Hatoum; Julia Sealock; Lea K Davis; Sarah L Elson; Abraham A Palmer
Journal:  Mol Psychiatry       Date:  2021-11-02       Impact factor: 13.437

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.